Compare STIM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | LUNG |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 97.1M |
| IPO Year | 2018 | 2020 |
| Metric | STIM | LUNG |
|---|---|---|
| Price | $2.34 | $2.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $6.00 | $3.70 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | $52,776,000.00 | ★ $90,497,000.00 |
| Revenue This Year | $8.63 | $0.33 |
| Revenue Next Year | $9.24 | $8.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.80 | $1.13 |
| 52 Week High | $3.44 | $3.25 |
| Indicator | STIM | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 61.23 |
| Support Level | $1.19 | $1.26 |
| Resistance Level | $2.31 | $3.25 |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 35.21 | 66.10 |
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.